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Recent studies suggest simultaneous or metachronous lesions in multiorgans characterized by elevated serum levels of IgG4
and abundant inﬁltration of IgG4-positive plasma cells with various degrees of ﬁbrosis. Two Japanese research committees for
IgG4-RD, one from ﬁbrosclerosis (Okazaki team) and the other from lymph proliferation (Umehara team) supported by the
“Research Program for Intractable Disease” of the Ministry of Health, Labor, and Welfare of Japan, have agreed with the uniﬁed
nomenclature as “IgG4-RD” and proposed the comprehensive diagnostic criteria (CDC) for IgG4-RD. Validation of the CDC
demonstrated satisfactory sensitivity for the practical use of general physicians and nonspecialists but low sensitivity in the organs
to be diﬃcult in taking biopsy specimens such as type1 autoimmune pancreatitis (IgG4-related AIP), compared with IgG4-related
sialadenitis/dacryoadenitis(Mikulicz’sdisease)andIgG4-relatedkidneydisease.AlthoughthediagnosticcriteriacoveringallIgG4-
RD are hard to be established, combination with the CDC and organ-speciﬁc diagnostic criteria should improve sensitivity.
1.Introduction
Recent studies have suggested simultaneous or metachro-
nous lesions in multiorgans characterized by elevated serum
levels of IgG4 and abundant inﬁltration of IgG4-positive
plasma cells with various degrees of ﬁbrosis, which lead us to
propose the concept of a systemic disease [1, 4, 10, 23, 24].
However, there are many synonyms suggesting a systemic
disease, such as IgG4-related autoimmune disease [1], IgG4-
related sclerosing disease [4], IgG4-related plasmacytic syn-
drome (SIPS) [23], IgG4-related multiorgan lymphoprolif-
erative syndrome (IgG4-MOLPS) [10], and systemic IgG4-
related disease, all of which may refer to the same conditions
[24, 25]( Table 1). To simplify these conditions, members of
two Japanese research committees for IgG4-related disease,
one from view of ﬁbrosclerosis (Chaired by Prof. Okazaki)
[24] and the other from lymph proliferation (Chaired by
Professor. Umehara H) [25], both of which are supported
by the “Research for Intractable Disease” Program from the
Ministry of Health, Labor, and Welfare of Japan, have
agreed with uniﬁcation of diﬀerent nomenclatures as “IgG4-
related disease (IgG4-RD)” and proposed the comprehensive
diagnostic criteria (CDC) for IgG4-RD [15]. As it still
remains unclear whether pathogenetic mechanisms in each
involved organ-are same or not, the term IgG4-RD was
appointed as minimally reﬂecting these conditions to avoid
misdiagnosis of malignancy as much as possible.
2.The Concept ofIgG4-RelatedDisease
The two Japanese research committees independently ana-
lyzed the clinical features and conditions of IgG4-RD and
ﬁnally resulted in the following consensus with close col-
laboration [15, 24, 25]. (1) Patients with IgG4-RD show2 International Journal of Rheumatology
Table 1: Nomenclatures of IgG4-related conditions.
Nomenclature Authors (year)
IgG4-related autoimmune
disease Kamisawa et al. [1] (2003)
IgG4-associated multifocal
systemic ﬁbrosis
van der Vliet and
Perenboom [2] (2004)
IgG4-related systemic disease Kamisawa et al. [3] (2004)
IgG4-related sclerosing disease Kamisawa et al.
[4–7] (2006)
Hyper-IgG4 disease Neild et al. [8] (2006)
IgG4-related disease Zen et al. [9] (2007)
Systemic IgG4 plasmacytic
syndrome (SIPS) Masaki et al. [10] (2009)
IgG4-related multiorgan
Lymphoproliferative syndrome
(IgG4-MOLPS)
Masaki et al. [10] (2009)
IgG4-associated disease Geyer et al. [11] (2010)
diﬀuse/focal organ enlargement, with mass-forming or
nodular/thickened lesions in various organs, including the
central nervous system [26], lachrymal/salivary glands [10,
23], thyroid gland [27, 28], lungs [29], pancreas [30, 31],
biliary duct [32], liver [33], gastrointestinal tract [34, 35],
kidneys [36], prostate gland [37], retroperitoneum [38],
skin [39], lymph nodes [5, 40, 41], and artery [42, 43].
These conditions are quite similar to multifocal idiopathic
ﬁbrosclerosis (MIF) [44]. (2) These multiorgan lesions may
occur synchronously or metachronously, with the promi-
nent inﬁltration of lymphocytes and IgG4-positive plas-
macytes with ﬁbrosis. (3) IgG4-RD mainly aﬀects middle-
aged to elderly men except for IgG4-related dacryoadeni-
tis/sialadenitis. Although clinical symptoms depending on
involved organs are relatively mild, some patients develop
serious complications such as obstructive jaundice due to
hepatic, gallbladder, or pancreatic lesions; hydronephrosis
due to retroperitoneal ﬁbrosis; respiratory symptoms due to
pulmonary lesions. (4) Steroid treatment is eﬀective in many
patientwithIgG4-RD.However,prognosisandriskfactorsof
recurrence still remain unclear. (5) Although the inﬁltration
of IgG4-positive cells and increased serum concentrations
of IgG4 characteristic of IgG4-RD, the severity of ﬁbrosis is
dependent on the individual organs involved. For example,
storiform ﬁbrosis and obliterative phlebitis are characteristic
ofpancreatic,biliarytract,andretroperitoneallesionsbutare
rarely observed in lachrymal/salivary glands or lymph nodes.
3.IgG4-RelatedDisease(IgG4-RD)asthe
Comprehensive Nomenclature [24,25]
In addition to MIF, there are many synonyms, such as IgG4-
related autoimmune disease [1], “IgG4-related sclerosing
disease” [4], IgG4-related plasmacytic disease (SIPS) [23],
and “IgG4 + sMOLPS” [10], all of which may refer to the
same conditions. It has been debated which one is the most
appropriate. Storiform ﬁbrosis and obliterative phlebitis are
characteristic of biliopancreatic, retroperitoneal, and renal
lesions, but rarely observed in lachrymal/salivary glands and
lymphnodes [24, 25]. Then, the nomenclature of “IgG4-
related sclerosing disease” is mainly based on the ﬁbrous
swollen organs, whereas those of “IgG4-SIPS” and “IgG4-
MOLPS” are based on lymphoplasmacytic proliferation and
swollen lymph nodes without ﬁbrosis [24, 25]. Although
most patients have multiorgan lesions synchronously or
metachronously, about 10–20% of the patients show a
solitary organ involved without conﬁrming other organ
involvement [24, 25]. Therefore, it is unclear whether the
pathogenetic mechanism is same among individual organs
or not. In addition to IgG4-RD, IgG4-associate conditions
such as high serum levels of IgG4 or abundant inﬁltration
of IgG4-positive cells were reported in some patients with
malignancy; pancreatic [6, 45], biliary [46] and salivary can-
cer [47], gastrointestinal sarcoma [48], and ocular adnexal
lymphoma [49–51]. Therefore, the term “systemic” may lead
us to misdiagnosis of other organ lesions showing IgG4-
related conditions in cases of malignancy [51]. Based on
these ﬁndings, the members of Umehara and Okazaki teams
haveagreedthattheterm“IgG4-relateddisease”isappointed
as minimally accepting these conditions at this moment.
4. Comprehensive Diagnostic Criteriafor
IgG4-RD [15, 24,25]
The patients with IgG-4-related disease show organ enlarge-
ment or nodular/hyperplastic lesions in organs in the
entire body, synchronously or metachronously, due to the
prominent inﬁltration and ﬁbrosis of lymphocytes and plas-
macytes; however, the causes of the disease are still not clear.
The organs known to be aﬀected include the central ner-
vous system, lacrimal/salivary glands, thyroid gland, lungs,
pancreas, biliary duct, liver, gastrointestinal tracts, kidneys,
prostate gland, retroperitoneum, skin, arteries, and lymph
nodes. Although it remains unclear whether this disease is
the same as multifocal ﬁbrosclerosis, that is a possibility.
Clinical symptoms vary depending on the organ in which
the lesions are located, which suggests that it is hard
to establish criteria covering all patients with IgG4-RD.
Therefore, speciﬁc diagnostic criteria are required for each
involved organ such IgG4-related Mikulicz’s disease (IgG4-
related dacryoadenitis/sialadenitis [12]( Table 2), type 1 AIP
(IgG4-related pancreatitis) [13]( Table 3), and IgG4-related
kidney disease [14, 41]( Table 4). However, these organ-
speciﬁc criteria do not cover other organs or are not familiar
to general clinicians and specialists. Moreover, to avoid
misdiagnosis of malignancy, all physicians have to know
this emerging disease entity and can make a diagnosis of
IgG4-RD.Therefore,the CDC forIgG4-RD,containing three
major criteria (clinical, hematological and histopathological
examinations), have been proposed for practical use of
generalphysiciansandnonspecialist[15](Table 5).Although
sensitivity of the CDC for deﬁnitive IgG4-RD is low in the
organstobediﬃcultintakingbiopsyspecimens,itcandetect
possible cases of IgG4-RD. In the probable or possible cases,
organ speciﬁc criteria should be used concurrently.International Journal of Rheumatology 3
Table 2: Diagnostic criteria for IgG4+ Mikulicz’s disease [12] (approved by the Japanese Society for Sj¨ ogren’s Syndrome, 2008).
(1) Symmetrical swelling of at least 2 pairs of lachrymal, parotid, and submandibular glands continuing for more than 3 months,
(2) elevated serum IgG4 (>135 mg/dL),
or
(3) histopathological features including lymphocyte and IgG4+ plasma cell inﬁltration (IgG4+ plasma cells/IgG+ plasma cells > 50%) with
typical tissue ﬁbrosis or sclerosis.
Diﬀerential diagnosis is necessary from other disorders, including sarcoidosis, Castleman’s disease, Wegener’s granulomatosis, lymphoma,
and cancer. Although the diagnostic criteria for Sj¨ ogren’s syndrome (SS) may also include some patients with IgG4+ Mikulicz’s disease, the
clinicopathological conditions of patients with typical SS and IgG4+ Mikulicz’s disease are diﬀerent.
(1) Clinical Examination. Physical examinations and imag-
ing on US/CT/MRI can show the characteristic diﬀuse/lo-
calized swelling, masses, or thickness in single or multiple
organs (Figure 1).
(2) Immunological Examination
(a) Increase of Serum Levels of IgG4. The cutoﬀ value for
serum IgG4 concentration, 135mg/dL, was based on receiver
operating characteristic (ROC) curves, and its validity was
conﬁrmed in patients with autoimmune pancreatitis [7]
(Table 6). In patients with single-organ involvement and
serumIgG4concentrationlessthan135mg/dL,theIgG4/IgG
ratio may be helpful in making a diagnosis.
However, elevated IgG4 may be also observed in other
diseases (e.g., atopic dermatitis, pemphigus, asthma, and
multicentric Castleman’s disease), especially in about 10% of
malignancy, which suggests that high serum IgG4 is not nec-
essarilyspeciﬁcmarkerofIgG4-RD[6].Althoughahighcut-
oﬀ value with >270mg/dL of IgG4 increases speciﬁcity but
decreased sensitivity of IgG4-RD diﬀering from pancreatic
cancer[45].Therefore,atpresent,thesigniﬁcanceofelevated
IgG4 in the pathogenesis/pathophysiology of IgG4-RD still
remains unknown.
(b) Other Immunological Markers. In addition to increased
serum levels of IgG4, high serum levels of polyclonal γ-
globulin, IgG, and IgE are often, and hypocomplementemia
may occur [52]. As these markers are less sensitive for IgG4-
RD, they are not included as a diagnostic criterion.
(3) Histopathologic Examination. Although tissue biopsies
are diﬃcult to obtain from some organs, including the pan-
creas, retroperitoneum and ocular cavity, histopathological
examination is important.
(a)MarkedLymphocyteandPlasmacyteInﬁltrationandFibro-
sis. Storiform or swirling ﬁbrosis or obliterative phlebitis
is Characteristic of IgG4-RD and may be important in its
diagnosis.
(b) Inﬁltration of IgG4-Positive Plasma Cells. IgG4/IgG-
positive cells more than 40% [53] or 50% [12]h a v eb e e n
reported in lymphnodes of the patients with IgG4-RD. On
the other hand, more than 10 IgG4-positive plasma cells are
recommended that in diagnosis of type 1 AIP [13]. Based
on these ﬁndings, the CDC for IgG4-RD recommend both
the ratio of IgG4/IgG-positive cells >40% and inﬁltration
of >10 IgG4-positive plasma cells/HPF for the deﬁnitive
diagnosis [15]. Eosinophilic inﬁltration is often observed
along with inﬁltration of IgG4-positive cells. It is noted that
reactive inﬁltration of IgG4-positive cells and ﬁbrosis may be
observed in various diseases and clinical conditions, such as
rheumatoid synovitis, inﬂammatory oral and skin lesions,
and around cancer. However, it is noted that some addi-
tional immune-mediated conditions with increased serum
interleukin-6 (IL-6) such as multicentric Castleman’s disease
may show elevated serum IgG4 and/or IgG4+/IgG+ plasma
cell ratios >40%.
(4) Prohibition of Facile Steroid Treatment in the CDC for
IgG4-RD. Patients with malignant lymphoma or parane-
oplastic lesions can sometimes be improved by steroid
administration. Therefore, steroid trials should be strictly
avoided. Eﬀorts should be made to collect tissue samples
for diagnosis. However, patients having disease in organs
diﬃcult to biopsy, such as the pancreas, retroperitoneum,
and pituitary, and respond to steroids may possibly have
IgG4-RD. In accordance with the guidelines for treatment of
autoimmune pancreatitis, patients should be started on 0.5-
0.6mg/kg/day/prednisolone. If patients do not respond to
the initial steroid therapy, the diagnosis should be reviewed
again.
(5) Diseases to be Excluded or Diﬀerentiated
(a) Malignancies (e.g., Cancer, Lymphoma). In cases of ma-
lignancy in the involved organs, it is essential to determine
whether malignant cells are present histopathologically.
(b) Similar Diseases. Other similar benign diseases includ-
ing Sj¨ ogren’s syndrome, primary sclerosing cholangitis,
multicentric Castleman’s disease, idiopathic retroperitoneal
ﬁbrosis, Wegener’s granulomatosis, sarcoidosis, and Churg-
Strauss syndrome should be diﬀerentially diagnosed using
the diagnostic criteria for each disease. It is noted that mul-
ticentric Castleman’s disease, one of hyper IL-6 syndromes
shouldbeexcludedfromIgG4-RD,eveniftheCDCforIgG4-
RD are fulﬁlled.4 International Journal of Rheumatology
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Table 4: Diagnostic criteria for IgG4-related kidney disease [14].
(1) Presence of some kidney damage, as manifested by abnormal urinalysis or urine marker(s) or decreased kidney function with either
elevated serum IgG or IgE or hypocomplementemia
(2) Abnormal renal radiologic ﬁndings:
(a) multiple low-density lesions on enhanced computed tomography;
(b) diﬀuse kidney enlargement;
(c) hypovascular solitary mass in the kidney;
(d) hypertrophic lesion of the renal pelvic wall without irregularities of the renal pelvic surface.
(3) Elevated serum IgG4 level (>135 mg/dL)
(4) Histological ﬁndings in the kidney:
(a) dense lymphoplasmacytic inﬁltration by >10 IgG4-positive plasma cells/high power ﬁeld (HPF) and/or IgG4+/IgG+ positive plasma
cells > 40%;
(b) characteristic (sclero-) ﬁbrosis surrounding nests of lymphocytes and/or plasma cells;
(5) Histological ﬁndings in extrarenal organ(s):
dense lymphoplasmacytic inﬁltration by >10 IgG4-positive plasma cells/HPF and/or IgG4/IgG-positive plasma cells > 40%
Deﬁnite: (1) + (3) + (4) (a), (b)
(2) + (3) + (4) (a), (b)
(2) + (3) + (5)
(1) + (3) + (4) (a) + (5)
Probable: (1) + (4) (a), (b)
(2) + (4) (a), (b)
(2) + (5)
(3) + (4) (a), (b)
Possible: (1) + (3)
(2) + (3)
(1) + (4) (a)
(2) + (4) (a)
Appendix:
(1) Clinically and histologically, the following diseases should be excluded:
Wegener’s granulomatosis, Churg-Strauss syndrome, and extramedullary plasmacytoma.
(2) Radiologically, the following diseases should be excluded:
Malignant lymphoma, urinary tract carcinomas, renal infarction, and pyelonephritis.
(Rarely, Wegener’s granulomatosis, sarcoidosisand metastatic carcinoma)
Table 5: Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011 [15].
[Concept]
IgG4-related disease (IgG4-RD) shows organ enlargement or nodular/hyperplastic lesions in various organs concurrently or
metachronously, due to marked inﬁltration of lymphocytes and IgG4-positive plasma cells, as well as ﬁbrosis of unknown etiology.
IgG4-RD aﬀects various organs, including the pancreas, bile duct, lacrimal gland, salivary gland, central nervous system, thyroid, lung,
liver, gastrointestinal tract, kidney, prostate, retroperitoneum, arteries, lymph nodes, skin, and breast. Although many patients with
IgG4-RD have lesions in several organs, either synchronously or metachronously, others show involvement of a single organ. Clinical
symptoms vary depending on the aﬀected organ, and some patients may experience serious complications, such as obstruction or
compression symptoms due to organomegaly or hypertrophy and organ dysfunction caused by cellular inﬁltration or ﬁbrosis. Steroid
therapy is often eﬀective.
[Comprehensive clinical diagnostic criteria for IgG4-RD, 2011]
(1) Clinical examination shows characteristic diﬀuse/localized swelling or masses in single or multiple organs.
(2) Hematological examination shows elevated serum IgG4 concentrations (≥135mg/dL).
(3) Histopathologic examination shows;
(1) marked lymphocyte and plasmacyte inﬁltration and ﬁbrosis
(2) inﬁltration of IgG4-positive plasma cells: ratio of IgG4/IgG positive cells > 40% and > 10 IgG4-positive plasma cells/HPF.
Deﬁnite: (1) + (2) + (3), Probable: (1) + (3), Possible: (1) + (2)
However, it is important to diﬀerentiate IgG4-RD from malignant tumors of each organ (e.g. cancer, lymphoma) and similar diseases (e.g.
Sj¨ ogren’s syndrome, primary sclerosing cholangitis, Castleman’s disease, secondary retroperitoneal ﬁbrosis, Wegener’s granulomatosis,
sarcoidosis, and Churg-Strauss syndrome) by additional histopathological examination. Even when patients cannot be diagnosed using
the CCD criteria, they may be diagnosed using organ-speciﬁc diagnostic criteria for IgG4RD.6 International Journal of Rheumatology
Table 6: Sensitivity and speciﬁcity of serum levels of IgG4 in patients with type 1 AIP.
Cut-oﬀ Sensitivity Speciﬁcity
mg/dL n Median/(range) n (vs cancer)
Japan 135
Okazaki et al. [16] 71 80% 410 (3–3670) 101 98%
Okazaki et al. [17] 52 73% 505 (43–1540) NS
Kawa et al. [18] 64 92% 618 (8–2855) 80 98%
Korea 135
Choi et al. [19] 30 73% 473 (10–1764) 76 99%
USA 140
Ghazale et al. [20] 45 76% 550 (16–2890) 135 90%
Raina et al. [21] 26 44% (8–825) NS
Italy 135
(focal) 55 66% 267 NS
Frulloni et al. [22]( d i ﬀuse) 32 27% 78
Table 7: Validation of a combination of CDC and organ-speciﬁc criteria for type 1 AIP.
Compared with pancreas cancer, the sensitivity of comprehensive criteria for deﬁnite/probable AIP was 0%, but 78% for possible AIP,
and speciﬁcity was 100% in any groups. Although it is hard to take an enough size of specimen in diagnosis of AIP malignancy can be
usually denied by EUS-FNA. Therefore, the CDC are enough for detecting possible AIP, but not for deﬁnite/probable AIP.
AIP (n = 60)
PaCa (n = 17)
Total (n = 77)
JPS 2006 ICDC for type 1 AIP CDC for IgG4-RD
Diagnosis of AIP Deﬁnite AIP Deﬁnite/probable AIP Deﬁnite/probable AIP Possible
sensitivity 70% 97% 0% 78%
speciﬁcity 100% 100% 100% 100%
PPV 100% 100% 0% 100%
NPV 49% 8% 100% 57%
accuracy 77% 95% 22% 83%
PaCa: pancreas cancer, PPV: positive predictive value, NPV: negative predictive value.
Sclerosing cholangitis
CBD GB
Retroperitoneal ﬁbrosis
swelling
Mikulicz AIP
hilar lymphnodes
Pseudotumor
of the liver
Nodule∼tumor
thickening
Figure 1: Clinical ﬁndings of IgG4-related disease. Physical examinations and imaging on US/CT/MRI can show the characteristic diﬀuse/
localized swelling, masses, or thickness in single or multiple organs.International Journal of Rheumatology 7
Denial
NO Yes
Probable
Organ involvement or damage
Deﬁnitive       Possible
NO Yes
None
Yes
Yes
NO NO
NO
Tissue biopsy
Tissue biopsy
Yes
None
Yes
Organ-speciﬁc criteria for
• IgG4-AIP
• IgG4-mikulicz
• IgG4-renal disease
IgG4/IgG>40%
(IgG4 cells/HPF>10)
IgG4/IgG>40%
(IgG4 cells/HPF>10)
Serum IgG4>135 mg
Figure 2: Diagnostic algorithm for IgG4-RD in Japan.
5. SensitivityandSpeciﬁcityof
the CDC CriteriaandDiagnostic
Algorithm for IgG4-RD
The sensitivity of CDC for deﬁnitive/probable IgG4-RD is
satisfactory in IgG4-related MD [12] and IgG4-related KD
[14], but not in type 1 AIP [6, 13]. The major reason of low
sensitivity in type 1 AIP is that enough biopsy samples of the
pancreas are not easily obtained in most of these patients.
In addition, endoscopic ultrasonography (EUS), guide ﬁne
needle aspiration (FNA), is available in a few of institutes
in Japan, for examples only 16 of 226 (7%) board member
institutes in Kink district of Japan Gastroenterological
EndoscopySociety(JGES).Ontheotherhand,thesensitivity
of the CDC for possible IgG4-RD is satisfactory in type 1
AIP (Table 7). In contrast, patients with type 1 AIP could not
be diagnosed by the comprehensive diagnostic criteria (0%)
for deﬁnite, because biopsies could not be obtained from
most of these patients. Therefore, combination of the CDC
and organ-speciﬁc criteria should increase the sensitivity of
diagnosis, even in the possible cases of IgG4-RD.
Based on these ﬁndings, a diagnostic algorithm for IgG4-
RD in combination with the CDC and other organ-speciﬁc
criteria has been proposed, although they have a limitation
to the utility of the criteria proposed [15]( Figure 2). In
patientswith(a)organenlargement,massornodularlesions,
or organ dysfunction, performing of both (b) measurement
of serum IgG4 and (c) tissue biopsy is recommended. In
the cases with >135mg/dL of IgG4, diagnostic histopatho-
logical ﬁndings of >10 IgG4 cells/HPF and an IgG4/IgG
cell ratio >40 can diagnose them as deﬁnitive AIP. In
possible or probable cases fulﬁlling criterion (a) with (b),
or (c), organ-speciﬁc criteria for each disease should be
applied. It is important to diﬀerentiate IgG4-RD from
malignant tumors of each organ (e.g., cancer, lymphoma)
and similar diseases (e.g., Sj¨ ogren’s syndrome, primary scle-
rosing cholangitis, Castleman’s disease, secondary retroperi-
toneal ﬁbrosis, Wegener’s granulomatosis, sarcoidosis, and
Churg-Strauss syndrome) by additional histopathological
examination. Future studies including other organ diseases
similar to IgG4-RD are needed to establish the diagnostic
eﬃcacy of CDC.
6. Conclusion
“All Japan Research Team for IgG4-RD” uniﬁed the nomen-
clatures as “IgG4-related disease (IgG4-RD)” and proposed
the comprehensive diagnostic criteria (CDC) for IgG4-RD.
TheCDCforIgG4-RDwasmadeforthepracticaluseandfor
generalphysicianstodiﬀerentiateIgG4-RDfrommalignancy
or similar diseases as much as possible. Although sensitivity
of the CDC for deﬁnitive IgG4-RD is low in the organs to8 International Journal of Rheumatology
be diﬃcult in taking biopsy specimens, it can detect possible
cases of IgG4-RD. In the probable or possible cases, organ-
speciﬁc criteria should be used concurrently.
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